Release Date: 31/01/20 10:13 Summary: Appendix 4C - quarterly Price Sensitive: Yes Download Document 176.75KB Download
TLX Telix gets its foot in the FDA door bringing prostate cancer detection closer to neglected Americans
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market